News from northwest biotherapeutics, inc. A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 01, 2018, 08:45 ET NW Bio Releases Vote Tallies From Special Shareholder Meeting

Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor...

Oct 30, 2017, 09:45 ET NW Bio Reports Favorable Results and Progress In Resolving Lawsuits

Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable...

Oct 25, 2017, 09:46 ET NW Bio Reports Favorable Results and Progress In Resolving Lawsuits

Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable...

Jun 22, 2017, 11:41 ET NWBio Closes 3-Year Convertible Debt Exchange and Financing, and Completes Payoff of Last $5 Million of 2014 Bonds

Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable...

Sep 21, 2016, 01:52 ET NW Bio Presents Updated Data From DCVax®-Direct Phase I Trial At 5th Annual SMi Cancer Vaccines Conference in London

Northwest Biotherapeutics (NASDAQ: NWBO)("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor...

May 02, 2016, 05:00 ET NW Bio Announces Operations Updates

Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor...

Feb 29, 2016, 10:58 ET NW BIO Announces Registered Direct Offering Of Up To $27.6 Million With Existing Institutional Investors

Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers,...

Jan 25, 2016, 12:43 ET NW Bio Presenting At Phacilitate Immunotherapy World Forum

Northwest Biotherapeutics, Inc. (NASDAQ: NWBO)("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable...

Jan 08, 2016, 09:15 ET NW Bio Issues Statement on Adverse Market Conditions And NW Bio Stock Decline

Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor...

Nov 30, 2015, 07:15 ET NW Bio Plans to Expand Board, Welcomes Woodford's Call For Independent Investigation Of Allegations In Anonymous Internet Report

Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor...

Jun 01, 2015, 11:44 ET NW Bio Announces Data to Date From DCVax®-Direct Phase I Trial

Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor...

May 27, 2015, 08:30 ET NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend

Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for cancer,...

May 21, 2015, 10:56 ET NW Bio To Present At New York Academy Of Sciences' Conference On Emerging Approaches To Immunotherapy

Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for cancer,...

May 01, 2015, 10:54 ET NW Bio Closes On $28.5 Million Second Tranche Of Woodford $40 Million Financing

Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor...

Apr 20, 2015, 06:00 ET NW Bio Featured In Presentations At the American Association for Cancer Research Annual Meeting

Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for cancer,...

Apr 16, 2015, 06:00 ET NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies"

Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing non-toxic DCVax® personalized immune therapies for...

Apr 09, 2015, 08:00 ET NW BIO TO PRESENT AT WORLD VACCINE CONGRESS 2015

Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing non-toxic DCVax® personalized immune therapies for...

Mar 27, 2015, 09:00 ET NW BIO REPORTS PROMISING SURVIVAL DATA IN 51 GBM PATIENTS TREATED WITH DCVAX®-L

Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for cancer,...

Mar 24, 2015, 10:42 ET NW Bio To Present At The 2nd Immunotherapy Of Cancer Conference, ITOC-2

Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for cancer,...

Feb 06, 2015, 09:15 ET NW Bio To Present At 17th Annual BIO CEO & Investor Conference

Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable...

Jan 23, 2015, 01:06 ET NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum

Northwest Biotherapeutics, Inc. (NASDAQ: NWBO)("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable...

Jan 08, 2015, 02:46 ET NW Bio To Present At Biotech Showcase Conference

Northwest Biotherapeutics, Inc. (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid...

Dec 11, 2014, 11:59 ET NW BIO RECAPS 2014 PROGRESS, PROVIDES DCVAX-DIRECT TRIAL UPDATE AT OPPENHEIMER'S 25TH ANNUAL HEALTHCARE CONFERENCE

Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor...

Nov 19, 2014, 03:20 ET NW BIO ANNOUNCES FINANCINGS TOTALING $35 MILLION TO EXPAND AND ACCELERATE DCVAX®-L AND DCVAX®-DIRECT PROGRAMS

Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor...

Oct 14, 2014, 09:01 ET DCVAX®-L HOSPITAL EXEMPTION PROGRAM NOW UNDER WAY IN GERMANY

Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, ...